I think you have valid points big. I guess the real difference is in the purity. No one makes a product as pure as that of AMRN. I agree it is a product that many have used however the benefit in their composition had been shown to be superior. Above that they have paid the costs of proving that and probably deserve compensation. I am not sure that it si right or wrong simply that it is.

The current product on the market sells 1 Billion/year and is less pure yet they have an FDA approved treatment that is also comprised of fish oil. Actually the ceo of amrn was the cfo of the company that created that product before it was bought out by big pharma.

So overall, you have better product with a big market potential and a ceo who knows the market well. I am not sure he would take the helm of a company as ceo if he thought it would crash and burn, (I know that thought can be flawed) The next indication they plan on going after could open the market up to a statin type market and the company anticipates filing an nda around year end for that indication.

As an investor, I think they could catch fire and their catalyst is near term. The initial indication is up for approval July 26th (or 27th). Beyond that their trial results were good even with a tough p value. Beyond that the fda has indicated that no panel will be called for their approval decision.

So the initial indication is  for a market that currently sells 1 bil/year with a potential overall market indicated in the 4 - 6 billion range. The second indication for mid level indication is estimated (by the company) in the 36 - 40 billion rage.

Just my 2 cents.

GLAS's - let look for an exciting two weeks. Go arna.....